Is upadacitinib appropriate for treating Crohn’s disease in children, and what are the dosing and safety considerations?

Upadacitinib for Crohn's Disease in Children

Upadacitinib is NOT currently approved for pediatric Crohn's disease, but emerging real-world evidence suggests it may be effective in highly refractory cases where standard therapies have failed, though this represents off-label use with important safety considerations.

Current Regulatory and Guideline Status

The most recent adult guidelines 1 from 2025 conditionally recommend upadacitinib for moderate to severe Crohn's disease in adults, specifically where anti-TNF therapies have failed or are not tolerated. However, no pediatric-specific guidelines exist for upadacitinib in Crohn's disease. The established pediatric Crohn's disease guidelines 2 from 2014 do not mention upadacitinib, as it was not available at that time. These guidelines recommend a stepwise approach starting with exclusive enteral nutrition (EEN) or corticosteroids for induction, followed by thiopurines or methotrexate for maintenance, with anti-TNF therapy reserved for high-risk patients or those failing conventional therapy.

Positioning in Pediatric Treatment Algorithm

Based on available evidence, upadacitinib should be considered only after:

• Failure of thiopurines (azathioprine 2-2.5 mg/kg/day or 6-mercaptopurine 1-1.5 mg/kg/day) 2
• Failure of methotrexate (15 mg/m² weekly, max 25 mg subcutaneously) 2
• Failure of or intolerance to anti-TNF therapy 2
• Consideration of other biologics (ustekinumab, vedolizumab) 3

This positioning mirrors the adult indication where upadacitinib is recommended "where anti-TNF have failed or are not tolerated or contraindicated" 1.

Emerging Pediatric Evidence

Efficacy Data

The most comprehensive pediatric data comes from recent real-world studies:

A 2026 meta-analysis 4 of 248 pediatric patients (114 with CD, 134 with UC) showed:

• Post-induction clinical response: 88% (95% CI: 76%-96%)
• Post-induction steroid-free clinical remission: 70% (95% CI: 54%-85%)
• Maintenance steroid-free clinical remission: 76% (95% CI: 59%-89%)

Individual cohort studies demonstrate variable CD-specific outcomes:

• One study 5 of 20 patients (3 CD, 13 UC, 4 IBD-U) showed 90% clinical response at weeks 8-12, with 75% achieving steroid-free remission post-induction
• Another study 6 of 20 adolescents (9 CD, 10 UC) showed 75% achieved week-12 steroid-free remission, maintained in 74% at 6 months
• A Chinese study 7 showed only 20% (1/5) clinical response in CD at week 12, though 2 eventually achieved remission at weeks 14-20 with combination therapy

Critical caveat: A 2026 study 8 identified a concerning pattern where 43.8% of pediatric patients lost response after transitioning from induction (45 mg daily) to maintenance dosing (30 or 15 mg daily), with median time to relapse of 81.5 days. However, 85.7% regained response when dose was increased back to induction levels.

Dosing Considerations

Adult-Approved Dosing (from FDA label 9):

• Induction: 45 mg once daily for 12 weeks
• Maintenance: 15 mg or 30 mg once daily (higher dose for those with prior anti-TNF failure)

Pediatric Dosing Considerations:

No established pediatric dosing exists. Real-world studies have used adult dosing in adolescents (typically ≥12 years, median age 15-16 years) 6, 5. The high relapse rate after dose reduction 8 suggests:

• Pediatric patients may require longer induction periods (beyond 12 weeks)
• Higher maintenance doses (30 mg vs 15 mg) may be necessary
• Weight-based dosing may be needed but is not yet established
• Close monitoring during transition from induction to maintenance is critical

Safety Profile in Pediatrics

Reported Adverse Events:

Real-world pediatric studies show acceptable safety with no new safety signals beyond those known in adults 5:

• Serious adverse event rate: 9 per 100 person-years 4
• Herpes zoster reactivation: 4 per 100 person-years 4
• Specific cases: CMV colitis requiring hospitalization 6, hyperlipidemia 6, norovirus with hypovolemic shock 7
• No venous thromboembolic events reported in pediatric cohorts 4

FDA Black Box Warnings (from adult data 9):

• Serious infections (including tuberculosis, opportunistic infections)
• Mortality (increased risk in patients ≥50 years with ≥1 cardiovascular risk factor)
• Malignancy and lymphoproliferative disorders
• Major adverse cardiovascular events (MACE)
• Thrombosis (VTE, pulmonary embolism)
• Gastrointestinal perforations

Important note: These warnings are based on adult rheumatoid arthritis data, particularly in older patients with cardiovascular risk factors. The relevance to pediatric IBD populations is unclear but requires vigilance.

Pre-Treatment Requirements

Before initiating upadacitinib, ensure:

1. Tuberculosis screening: Test for latent TB and treat if positive before starting 2
2. Varicella zoster immunity: Check history and serology; vaccinate seronegative patients before immunosuppression 2
3. Complete vaccination status: Update all vaccines, particularly live vaccines before starting 2
4. Hepatitis B screening: Check HBsAg and anti-HBc
5. Baseline laboratory monitoring: CBC, liver enzymes, lipid panel 9

Monitoring During Therapy

Laboratory monitoring:

• CBC and liver enzymes: Regularly (specific intervals not established for pediatrics)
• Lipid panel: Periodically (hyperlipidemia reported 6)
• Inflammatory markers: CRP, fecal calprotectin to assess response

Clinical monitoring:

• Disease activity scores: PCDAI at weeks 4,8,12, then every 8-12 weeks
• Growth parameters: Height, weight, Tanner staging
• Watch for medication residue in stool (may indicate inadequate absorption) 9
• Monitor for infections, particularly herpes zoster

Combination Therapy Considerations

Limited data exist on combination therapy in pediatrics. One study 5 used upadacitinib as monotherapy in 55% and combined with ustekinumab (35%) or vedolizumab (10%). Another study 7 combined upadacitinib with thalidomide or exclusive enteral nutrition in CD patients with persistent activity. The safety and efficacy of combination approaches require further study.

Clinical Decision Algorithm

For pediatric Crohn's disease patients who have failed:

1. First-line: EEN or corticosteroids + thiopurines 2
2. Second-line: Anti-TNF therapy (infliximab or adalimumab) 2
3. Third-line: Alternative biologics (ustekinumab, vedolizumab) 3
4. Fourth-line consideration: Upadacitinib (off-label)

Upadacitinib may be considered earlier if:

• Multiple biologic failures with limited options
• Severe growth retardation requiring rapid response
• Perianal disease refractory to standard therapy
• Patient/family preference for oral therapy over infusions
• Contraindications to other biologics

Do NOT use upadacitinib if:

• Active serious infection
• Untreated latent tuberculosis
• History of malignancy
• Age <12 years (insufficient data)
• Pregnancy or breastfeeding

Practical Implementation

Starting therapy:

• Begin with 45 mg once daily (adult induction dose)
• Assess response at week 4 (earlier than standard week 12 for adults)
• Continue induction for at least 12 weeks, potentially longer based on response 8

Transitioning to maintenance:

• Consider 30 mg daily (not 15 mg) given high relapse rates with lower doses 8
• Monitor closely for 3 months after dose reduction
• If relapse occurs, increase back to 45 mg daily 8
• Consider maintaining 45 mg daily in severe cases or those with prior rapid relapse

Managing inadequate response:

• Optimize dose before declaring failure
• Consider combination with EEN or other agents 7
• Evaluate for medication residue in stool (may indicate malabsorption) 9
• Check drug levels if available (not yet standardized)

Key Limitations and Caveats

1. All pediatric data are retrospective, off-label use - no randomized controlled trials exist
2. Small sample sizes - largest meta-analysis includes only 114 CD patients 4
3. Short follow-up - median 28-51 weeks in most studies
4. Selection bias - patients were highly refractory with multiple prior biologic failures
5. Variable CD response - some studies show excellent results 6, 5, others show poor initial response requiring combination therapy 7
6. Dosing uncertainty - optimal pediatric dosing, particularly for maintenance, remains undefined
7. Long-term safety unknown - cardiovascular and malignancy risks require years of follow-up

Bottom Line

Upadacitinib represents a potential rescue therapy for adolescents (≥12 years) with highly refractory Crohn's disease who have exhausted standard options, but it should be used with caution, close monitoring, and informed consent regarding off-label use and potential risks. The convenience of oral administration and emerging efficacy data make it attractive, but the lack of pediatric trials, uncertain optimal dosing (particularly for maintenance), and serious safety warnings mandate careful patient selection and vigilant follow-up. Consider maintaining higher doses (30-45 mg daily) longer than adult protocols suggest, given the high relapse rate with dose reduction in pediatric patients.